Vienna health informatics SME applying federated machine learning and digital platforms to rare disease diagnosis and privacy-preserving clinical data sharing.
RESEARCH INSTITUTE AG & CO KG is a Vienna-based private research SME specialising in health informatics and digital health technologies. Their work sits at the intersection of machine learning, privacy-preserving data architectures, and clinical data systems — building tools that allow medical data to be analysed across institutions without centralising sensitive records. In FeatureCloud they contributed to federated learning and blockchain infrastructure for healthcare cybersecurity, while in SCREEN4CARE they are applying machine-learning phenotypic analysis and electronic health record integration to accelerate rare disease diagnosis via newborn genetic screening. Their practical focus is on turning distributed clinical data into actionable diagnostic intelligence, particularly for under-served patient populations with rare diseases.
FeatureCloud was explicitly about privacy-preserving federated ML in healthcare, and SCREEN4CARE employs a machine-learning phenotypic checker — federated approaches appear in both projects.
SCREEN4CARE (2021–2026) directly targets rare and neuromuscular diseases through newborn genetic screening and digital diagnostic tools.
SCREEN4CARE involves EHR integration and a dedicated digital platform for shortening the path to rare disease diagnosis.
FeatureCloud used blockchain alongside federated learning specifically to reduce cybersecurity risks in sensitive health data sharing across institutions.
FeatureCloud lists bioinformatics and medical informatics as core keywords, indicating capability in computational biology pipelines and clinical data modelling.
Their H2020 participation opened with a focus on the data infrastructure layer — federated machine learning, blockchain, and privacy-preserving architectures as a response to cybersecurity risks in distributed health data environments. By 2021 the emphasis shifted decisively toward clinical application: rare disease diagnosis, newborn screening programmes, genetic testing, and EHR-integrated digital platforms. The thread connecting both phases is machine learning applied to sensitive, distributed health records — but the organisation has moved from building the privacy scaffolding to deploying it in specific high-impact clinical contexts, particularly rare and neuromuscular diseases.
They are moving from foundational data-privacy infrastructure toward applied clinical decision support — suggesting future work will likely involve AI-assisted diagnostics, genetic data platforms, or patient registry systems for rare diseases.
This organisation has participated exclusively as a consortium partner rather than a coordinator across both projects, indicating they join as a specialist contributor rather than a project driver. Their consortia are notably large — 47 unique partners across 17 countries from just two projects — suggesting they operate in ambitious, multi-stakeholder research networks rather than tight bilateral collaborations. This profile fits an organisation that brings a specific technical capability (federated ML, health informatics) to consortia that need that component without necessarily leading the programme management.
Despite only two projects, they have built a network of 47 distinct partners spanning 17 countries, indicating involvement in large pan-European consortia with broad international reach. Their projects cover both the security and health pillars of Horizon 2020, giving them cross-disciplinary network exposure beyond a single research community.
This is a rare combination in the Austrian SME landscape: a private research company with hands-on expertise in both the privacy-preserving infrastructure for health data (federated learning, blockchain) and the clinical application layer (rare disease diagnosis, genetic screening, EHR systems). Most health informatics players are either pure infrastructure or pure clinical — this organisation bridges both, which makes them a credible partner when a consortium needs someone who understands both the data governance constraints and the medical use case. Their SME status also means they can move faster and engage more flexibly than university research groups in similar niches.
